Diaorigin
Biotechnology
Biotechnology
Our expertise
Cell line for recombinant antibody production
Hybridoma conversion to CHO expression
Diaorigin Expert in cell lines and recombinant antibodies
Re-expression of antibodies without hybridoma
Rapid recombinant antibody discovery
SwiMR - patented technology
Dr. Yu explains...
Dr. Bo Yu, founder of Diaorigin Biotechnology, patent holder of SwiMR and AMR technology, explains the advantages of our technologies.
Recombinant antibodies
A recombinant antibody is a synthetic monoclonal antibody that is generated by recombinant DNA technology; an in vitro alternative to the traditional hybridoma-based technology for creating monoclonal antibodies. Recombinant antibodies are generated outside the immune system using synthetic genes and therefore do not require animal immunization for their production. These synthetic antibodies can be used in all applications and have several advantages compared to traditional animal-derived antibodies.
What are the advantages ?
01
Stablility
Superior Lot-to-Lot Consistency
02
Scalability
Amenable to large-scale production
03
Engineerable
Knowing sequence possible for all engineering
04
Animal-free
Cellular expression avoid the need to use animals
>>> Learn more
DiaBooster Hyper-Expression Plate-forme
Increase expression up to 10 - 15 g/L
DiaBooster CHO-K1A cell line is an adapted suspension cell line derived from CHO-K1, characterized by its ability to produce complex proteins similar to those in humans and its high tolerance for variations in pH, oxygen levels, temperature or cell density. It is capable to expand expression to 10-20 folds after Fed-Batch culture, which makes it ideal for large-scale recombinant antibody manufacturing.
Beacon single B cell sorting
The Beacon single B cell sorting system can introduce thousands of single cells into the nano-level micro-reaction chamber in one experiment through photoelectric positioning technology and microfluidic technology for integrated operations of single cell separation, detection, culture and export.
By using this technology, we are capable to obtain high-affinity monoclonal antibodies within 35 days, greatly accelerates the process of antibody discovery.
